Anna Lena Lopez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7187697/publications.pdf

Version: 2024-02-01

55 3,490 26
papers citations h-index

26 56
sindex g-index

58 all docs

58 docs citations 58 times ranked 2993 citing authors

#	Article	IF	CITATIONS
1	Epidemiology of Japanese encephalitis in the Philippines prior to routine immunization. International Journal of Infectious Diseases, 2021, 102, 344-351.	1.5	6
2	Timeliness of childhood vaccinations in the Philippines. Journal of Public Health Policy, 2021, 42, 53-70.	1.0	6
3	Cholera in selected countries in Asia. Vaccine, 2020, 38, A18-A24.	1.7	9
4	Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies. Vaccine, 2020, 38, 2833-2840.	1.7	12
5	Trends in dengue research in the Philippines: A systematic review. PLoS Neglected Tropical Diseases, 2019, 13, e0007280.	1.3	14
6	Urine Xpert MTB/RIF for the diagnosis of childhood tuberculosis. International Journal of Infectious Diseases, 2019, 79, 44-46.	1.5	8
7	Prospects for rotavirus vaccine introduction in the Philippines: Bridging the available evidence into immunization policy. Human Vaccines and Immunotherapeutics, 2019, 15, 1260-1264.	1.4	5
8	Feasibility of a Comprehensive Targeted Cholera Intervention in The Kathmandu Valley, Nepal. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1088-1097.	0.6	16
9	Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2018, 66, 1960-1971.	2.9	21
10	Impact of rotavirus vaccine on diarrheal hospitalization and outpatient consultations in the Philippines: First evidence from a middle-income Asian country. Vaccine, 2018, 36, 3308-3314.	1.7	7
11	Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?. Human Vaccines and Immunotherapeutics, 2018, 14, 495-499.	1.4	23
12	Cholera prevention and control in Asian countries. BMC Proceedings, 2018, 12, 62.	1.8	9
13	Effectiveness of monovalent rotavirus vaccine in the Philippines. Scientific Reports, 2018, 8, 14291.	1.6	17
14	Introduction of inactivated poliovirus vaccine in the Philippines: Effect on health care provider and infant caregiver attitudes and practices. Vaccine, 2018, 36, 7399-7407.	1.7	3
15	Hepatitis B seroprevalence among 5 to 6Âyears old children in the Philippines born prior to routine hepatitis B vaccination at birth. Human Vaccines and Immunotherapeutics, 2018, 14, 2491-2496.	1.4	2
16	Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine, 2017, 35, 5535-5542.	1.7	46
17	Cholera outbreak in Yemen. The Lancet Gastroenterology and Hepatology, 2017, 2, 777.	3.7	6
18	The burden of congenital rubella syndrome in the Philippines: results from a retrospective assessment. Western Pacific Surveillance and Response Journal: WPSAR, 2017, 8, 17-24.	0.3	3

#	Article	IF	Citations
19	Rubella and Congenital Rubella Syndrome in the Philippines: A Systematic Review. International Journal of Pediatrics (United Kingdom), 2016, 2016, 1-8.	0.2	2
20	Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design. Vaccine, 2016, 34, 479-485.	1.7	15
21	The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans. Lancet Infectious Diseases, The, 2016, 16, 125-129.	4.6	11
22	Evaluation in Cameroon of a Novel, Simplified Methodology to Assist Molecular Microbiological Analysis of V. cholerae in Resource-Limited Settings. PLoS Neglected Tropical Diseases, 2016, 10, e0004307.	1.3	19
23	Assessing different measures of population-level vaccine protection using a case–control study. Vaccine, 2015, 33, 6878-6883.	1.7	7
24	Epidemiology of Japanese Encephalitis in the Philippines: A Systematic Review. PLoS Neglected Tropical Diseases, 2015, 9, e0003630.	1.3	32
25	Flexibility of Oral Cholera Vaccine Dosing—A Randomized Controlled Trial Measuring Immune Responses Following Alternative Vaccination Schedules in a Cholera Hyper-Endemic Zone. PLoS Neglected Tropical Diseases, 2015, 9, e0003574.	1.3	27
26	Epidemiology of Cholera in the Philippines. PLoS Neglected Tropical Diseases, 2015, 9, e3440.	1.3	16
27	Updated Global Burden of Cholera in Endemic Countries. PLoS Neglected Tropical Diseases, 2015, 9, e0003832.	1.3	854
28	Mass Vaccination with a New, Less Expensive Oral Cholera Vaccine Using Public Health Infrastructure in India: The Odisha Model. PLoS Neglected Tropical Diseases, 2014, 8, e2629.	1.3	58
29	Post-licensure deployment of oral cholera vaccines: a systematic review. Bulletin of the World Health Organization, 2014, 92, 881-893.	1.5	57
30	Oral Cholera Vaccine Development and Use in Vietnam. PLoS Medicine, 2014, 11, e1001712.	3.9	22
31	Killed oral cholera vaccines: history, development and implementation challenges. Therapeutic Advances in Vaccines, 2014, 2, 123-136.	2.7	53
32	Vibriocidal Antibody Responses to a Bivalent Killed Whole-Cell Oral Cholera Vaccine in a Phase III Trial in Kolkata, India. PLoS ONE, 2014, 9, e96499.	1.1	15
33	5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2013, 13, 1050-1056.	4.6	201
34	Herd Protection by a Bivalent Killed Whole-Cell Oral Cholera Vaccine in the Slums of Kolkata, India. Clinical Infectious Diseases, 2013, 56, 1123-1131.	2.9	67
35	Risk Map of Cholera Infection for Vaccine Deployment: The Eastern Kolkata Case. PLoS ONE, 2013, 8, e71173.	1.1	17
36	The global burden of cholera. Bulletin of the World Health Organization, 2012, 90, 209-218.	1.5	409

#	Article	IF	Citations
37	Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy. PLoS Neglected Tropical Diseases, 2012, 6, e1743.	1.3	41
38	Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infectious Diseases, The, 2012, 12, 837-844.	4.6	115
39	Burden of Pneumonia and Meningitis Caused by Streptococcus pneumoniae in China among Children under 5 Years of Age: A Systematic Literature Review. PLoS ONE, 2011, 6, e27333.	1.1	62
40	Tetracycline-Resistant <i>Vibrio cholerae</i> O1, Kolkata, India. Emerging Infectious Diseases, 2011, 17, 568-569.	2.0	29
41	Use of Oral Cholera Vaccines in an Outbreak in Vietnam: A Case Control Study. PLoS Neglected Tropical Diseases, 2011, 5, e1006.	1.3	68
42	Efficacy of a Low-Cost, Inactivated Whole-Cell Oral Cholera Vaccine: Results from 3 Years of Follow-Up of a Randomized, Controlled Trial. PLoS Neglected Tropical Diseases, 2011, 5, e1289.	1.3	137
43	Community Participation in Two Vaccination Trials in Slums of Kolkata, India: A Multi-level Analysis. Journal of Health, Population and Nutrition, 2010, 28, 450-7.	0.7	11
44	Use of verbal autopsy to determine mortality patterns in an urban slum in Kolkata, India. Bulletin of the World Health Organization, 2010, 88, 667-674.	1.5	22
45	Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania. Bulletin of the World Health Organization, 2010, 88, 556-559.	1.5	31
46	Cholera Outbreaks Caused by an Altered Vibrio cholerae O1 El Tor Biotype Strain Producing Classical Cholera Toxin B in Vietnam in 2007 to 2008. Journal of Clinical Microbiology, 2009, 47, 1568-1571.	1.8	104
47	Classification of hybrid and altered Vibrio cholerae strains by CTX prophage and RS1 element structure. Journal of Microbiology, 2009, 47, 783-788.	1.3	27
48	Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: A randomized, placebo-controlled trial. Vaccine, 2009, 27, 6887-6893.	1.7	74
49	Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1694-1702.	6.3	227
50	The High Burden of Cholera in Children: Comparison of Incidence from Endemic Areas in Asia and Africa. PLoS Neglected Tropical Diseases, 2008, 2, e173.	1.3	150
51	Cholera vaccines for the developing world. Hum Vaccin, 2008, 4, 165-169.	2.4	45
52	Vaccine Protection of Bangladeshi Infants and Young Children Against Cholera. Pediatric Infectious Disease Journal, 2008, 27, 33-37.	1.1	40
53	A Randomized, Placebo-Controlled Trial of the Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults and Children in a Cholera Endemic Area in Kolkata, India. PLoS ONE, 2008, 3, e2323.	1.1	105
54	Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine, 2007, 25, 1149-1155.	1.7	95

#	Article	IF	CITATIONS
55	Effect of Heat Inactivation of Serum on Bordetella pertussis Antibody Determination by Enzyme-linked Immunosorbent Assay. Diagnostic Microbiology and Infectious Disease, 1998, 30, 21-24.	0.8	11